ENTA at Leerink: Phase-1 trials of ABT-493 and ABT-530 are completed, and dose-ranging phase-1b monotherapy trials are underway for each drug. Data from phase-1 to be released at unspecified venue in 2014.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”